

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  14D1078862	<b>(X3) Date Survey Completed</b>  01/08/2020
<b>Name of Provider or Supplier</b>  Alpha Medical Llc	<b>Street Address, City, State</b>  8635 Lemont Rd, Downers Grove, IL	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on surveyor review of CASPER Report 155 Proficiency Testing (PT) records, and phone communication with the PT vendor American Association of Bioanalysts (AAB); it was confirmed that the laboratory failed to successfully participate in the testing of PT samples under the specialty of Diagnostic Immunology. Findings include: 1. Review of PT CASPER Report 155 on January 06, 2020 at 8:00 AM revealed that the unsatisfactory PT performance occurred during events 2 and 3 of calendar year 2019. See D2084.</p>
<b>D2084</b>	<b>GENERAL IMMUNOLOGY</b>

CFR(s): 493.837(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on surveyor review of CASPER Report 155 Proficiency Testing (PT) records, and phone communication with the PT vendor American Association of Bioanalysts (AAB); it was confirmed that the laboratory failed to successfully participate in the testing of PT samples under the specialty of Diagnostic Immunology. Findings include: 1. Review of PT CASPER Report 155 on January 06, 2020 at 8:00 AM, revealed that the unsatisfactory PT performance occurred during calendar year 2019 for events 2 and 3 under General Immunology and Cholesterol Total as listed below. DIAGNOSTIC IMMUNOLOGY General Immunology, EVENT-2, 2019 = 50% Unsuccessful General Immunology, EVENT-3, 2019 = 0% Unsuccessful Cholesterol Total, EVENT-2, 2019 = 60% Unsatisfactory Cholesterol Total, EVENT-3, 2019 = 0% Unsatisfactory 2. During PT Desk review on January 06, 2020 and phone communication with the PT vendor AAB on 01/08/2020 at 10:12 AM, the PT failing scores were confirmed.